Supreme Court: US genes patent decision may depend on strands in Myriad argument

In June, the Supreme Court will release its decision on whether genes may be patented, which will have a far-reaching impact on the biotechnology industry. A Financial Times article on the subject quoted Andrew Torrance, professor of law.

Kirchgaessner wrote:

"It was obvious from the questions they asked and analogies that they dreamt up that the nine US Supreme Court justices hearing one of the most important and complex patent cases in a decade were not wholly comfortable with the subject at hand.

Who Owns Your Genes?

The U.S. Supreme Court will hear a case today that could decide whether human genes can be patented.  But the case is about more than just genetics.  It’s about how medical research gets funded, who profits from it, and who has access to its benefits.  Health Reporter Bryan Thompson sat down with University of Kansas Law Professor Andrew Torrance, who specializes in biotechnology patent law, for some clarification.

Biotech Industry at Stake in Human Gene Patent Decision

An article discussing the Supreme Court's plan to rule on whether human genes can be patented featured commentary from Andrew Torrance, professor of law.

“There is a strong aversion to patents that cover any aspect of the human body,” said Andrew Torrance, who teaches patent and biodiversity law at the University of Kansas and is a visiting scholar at the Massachusetts Institute of Technology. “It’s a gut-level principle. We don’t like the thought of humans as property, and we think of patents as property.”

Subscribe to RSS - gene patenting